Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OCUL
STRONG SELLOcular Therapeutix, Inc. · Healthcare · United States · $1.9B · Avg Vol: $24M/d
COMPANY DESCRIPTION
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company's competitive moat is anchored by its proprietary bioresorbable hydrogel platform, which enables sustained-release drug delivery and eliminates the need for daily eye drops. It operates as a leading ophthalmic innovator with a commercialized product portfolio and a high-potential clinical pipeline targeting wet AMD.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.5M | 58.4M | 63.7M | 52.0M | 0.3% | 52.0M | 51.9M | 120.4M | 52.2% |
| EPS | -0.32 | -1.01 | -1.22 | -1.42 | — | -1.40 | -1.55 | -1.54 | — |
| Shares | 219.0M | 115.0M | 157.7M | 215.9M | -1.4% | 219.0M | — | — | — |
| Debt | 64.3M | 83.4M | 75.8M | 77.0M | 6.2% | 79.5M | — | — | — |
| Equity | 35.4M | 91.1M | 315.3M | 654.3M | 164.5% | — | — | — | — |
| Op CF | -59.6M | -70.2M | -134.7M | -204.9M | — | -226.2M | — | — | — |
| Inv CF | -3.7M | -6.1M | -1.3M | -11.9M | — | — | — | — | — |
| Fin CF | 1.5M | 169.8M | 332.1M | 561.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OCUL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc.(you) | $1.9B | 9 | STRONG SELL |
| KARD | Kardigan, Inc. | $1.9B | 8 | STRONG SELL |
| GENB | Generate Biomedicines, Inc. | $1.7B | 8 | STRONG SELL |
| KLRA | Kailera Therapeutics, Inc. | $2.3B | 9 | STRONG SELL |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 11 | STRONG SELL |
| VERA | Vera Therapeutics, Inc. | $2.5B | 9 | STRONG SELL |
| MPLT | MapLight Therapeutics, Inc. | $1.7B | 14 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 16 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.6B | 5 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%